ReviewCardiovascular and interventional radiology2026
Endovascular Iliac Vein Revascularization Versus Conservative Management for Chronic, Symptomatic Iliac Vein Obstruction: A Systematic Review and Meta-Analysis.
Review in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo synthesize the existing evidence comparing endovascular iliac vein revascularization versus conservative management for chronic, symptomatic venous obstruction. MATERIALS AND
methodsWe searched PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov for comparator-controlled studies of endovascular iliac vein revascularization versus conservative management. The primary outcome was the Venous Clinical Severity Score (VCSS); secondary outcomes were the Villalta score, Venous Insufficiency Epidemiological and Economic Study Quality of Life (VEINES-QOL), and Visual Analogue Scale (VAS) pain. Continuous outcomes were pooled as mean differences (MD) using random-effects models with the Hartung-Knapp-Sidik-Jonkman adjustment. Certainty was assessed with GRADE (PROSPERO CRD420261446246).
resultsFour studies (three randomized trials, one cohort; 554 patients; n per outcome: VCSS 317, Villalta 479, VAS 267, VEINES-QOL 274) met eligibility. Revascularization reduced VCSS (MD - 2.24, 95% confidence interval [CI] - 3.86 to -0.63) and the Villalta score (MD - 3.48, 95% CI - 4.75 to - 2.21; both I
conclusionRevascularization reduced venous symptom severity under the primary model, though neither estimate was robust to omitting individual studies, and the VCSS prediction interval crossed the null. Bleeding risk was increased in the largest trial; quality-of-life and pain effects were inconclusive. The evidence offers modest support for revascularization in patients failing conservative therapy, with short follow-up.
Indexed as
Identifiers
42811133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.